BD generated $18.9bn revenue in the full fiscal year 2022, a 1.4% decrease compared to the previous year. Credit: SKreutz / commons.wikimedia.org.

Becton, Dickinson and Company (BD) has reported $4.76bn revenue in the fourth quarter (Q4) of the fiscal year 2022, representing a 1.8% decline compared to $4.84bn in the same quarter of the previous year.

The revenue performance was driven by 4.2% growth in base revenue, reaching $4.72bn from $4.5bn reported the prior year, and 8.6% on a currency-neutral basis.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

During the quarter, the company’s GAAP stood at $0.92, while adjusted diluted EPS was at $2.75.

The company’s BD Medical segment reported $2.3bn in revenues, representing a 5.8% increase from $2.2bn in the same quarter of the previous year.

In the BD Life Sciences segment, $1.28bn revenue was generated, a 15.9% decline from the year-ago quarter.

The BD Interventional segment generated $1.09bn revenue, showing a 2.4% increase from the year-ago quarter.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

For the full year of fiscal 2022, BD generated $18.9bn revenue, a 1.4% decrease and 0.9% increase on a currency-neutral basis.

Its revenue performance was driven by 6.9% growth and 9.4% on a currency-neutral basis.

GAAP for the complete fiscal year 2022 stood at $5.38 and the adjusted diluted EPS at $11.35.

BD chairman, CEO and president Tom Polen said: “Fiscal 2022 was another outstanding year with impactful results that confirm the effectiveness of our BD 2025 strategy.

“We delivered reliable, consistent performance that reflects our team’s unwavering commitment to our purpose and the execution of our growth plan – while navigating the challenging macro environment all companies are facing.

“Looking forward, our strong performance and momentum increases our confidence to continue to create substantial, sustained value for all stakeholders.”

Recently, the company launched the BD Research Cloud software solution in the US as well as the BD Effivax next-generation glass prefillable syringe.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact